Biotech · Private company · Cambridge, MA, US
2seventy bio, Inc.
SEC CIK 0001860782
Track this companyFree. Adds 2seventy bio, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials21 recruiting or active
Pipeline programs1From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline1
- bb21217Phase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell TransplantationPHASE3 · ACTIVE_NOT_RECRUITING · started Oct 16, 2023ClinicalTrials.gov NCT06045806 · fetched Nov 12, 2026
- Study of bb21217 in Multiple MyelomaPHASE1 · COMPLETED · started Aug 16, 2017ClinicalTrials.gov NCT03274219 · fetched Nov 12, 2026
SEC filings9
- 8-K · FORM 8-KSEC EDGAR · filed May 13, 2025 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 7, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 7, 2025 · fetched Nov 12, 2026
- 10-K/A · 10-K/ASEC EDGAR · filed Apr 28, 2025 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 25, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 25, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 11, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 6, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jan 10, 2025 · fetched Nov 12, 2026